ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD19/CD3 Bispecific Antibody MK-1045

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Lymphoma, Non-Hodgkin · Burkitt Lymphoma · Lymphoma, Large B-Cell, Diffuse, led by Merck.

Drug pageAnti-CD19/CD3 Bispecific Antibody MK-1045: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 29, 20268 company-led studies, 8 open or runningNext primary completion: Sep 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck88 open or runningphase 3since Apr 29, 2026Oct 7, 2022Sep 30, 2028phase 1 · NCT06189391
  • Named in Merck’s own pipeline as MK-1045, phase 2, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2022First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT05579132 · 203 planned · China
  2. Aug 30, 2023Phase 1 study in RecurrenceNCT06189391 · 100 planned · China
  3. Jan 16, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07363590 · 21 planned · Australia, Belgium, China and more
  4. Apr 3, 2026Phase 2 study in Lymphoma, Non-HodgkinNCT07519772 · 280 planned · United States, Argentina, Australia and more
  5. Apr 29, 2026Phase 3 study in Burkitt LymphomaPhase 3 reachedNCT07570173 · 340 planned · Canada, Denmark, France and more
  6. Jun 4, 2026Phase 3 study in Lymphoma, FollicularNCT07634471 · 960 planned · United States, Argentina, Australia and more
  7. Jul 13, 2026Phase 2 study in Leukemia, B-CellNCT07709000 · 60 planned · Colombia, Israel, Spain
  8. Oct 28, 2026Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07917754 · 470 planned

Ahead

  1. Sep 30, 2028Primary completion: phase 1 study in RecurrenceNCT06189391
  2. Dec 31, 2028Primary completion: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT05579132
  3. Jul 16, 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07363590
  4. Jul 1, 2030Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07519772

TargetBeta

“An immunoglobulin G4 (IgG4) bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 bispecific antibody MK-1045 binds to …”NCIt, read by Claude
“An immunoglobulin G4 (IgG4) bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
surovatamigAstraZenecaphase 310
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07917754Lymphoma, Large B-Cell, Diffuse3Not yet recruitingMar 13, 2037470
NCT07709000Leukemia, B-Cell · Colombia, Israel, Spain2RecruitingNov 16, 203360
NCT07634471Lymphoma, Follicular · United States, Argentina, Australia and more3RecruitingJul 23, 2032960
NCT07570173Burkitt Lymphoma · Canada, Denmark, France and more3RecruitingOct 18, 2033340
NCT07519772Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more2RecruitingJul 1, 2030280
NCT07363590Lupus Erythematosus, Systemic · Australia, Belgium, China and more1RecruitingJul 16, 202921
NCT06189391Recurrence · China1RecruitingSep 30, 2028100
NCT05579132Precursor Cell Lymphoblastic Leukemia-Lymphoma · China2RecruitingDec 31, 2028203

How it is read

Names in the registry

  • “MK-1045”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.